title: Quantitative EEG and BPRS data following Haldol-Decanoate administration in schizophrenics.
abstract: Approximately one-third of schizophrenic patients receiving antipsychotic drugs obtain little or no benefit from them. In some reports, response has been linked with "prognostic" factors, including abnormal EEG and drug response (pharmaco-EEG). Measurements of topological EEG spectral power and Brief Psychiatric Rating Scale (BPRS) values were obtained in 15 schizophrenics over a period of 20 min immediately after the first application, and at weekly intervals after single intramuscular injection of 2 ml depot haloperidol (Haldol-Decanoate). A highly significant increase in the alpha-1 power density at almost all positions and an increase in theta power at parietotemporal regions can be described as electrophysiological parameters of the acute pharmaco-EEG. BPRS values decreased continuously within the first 2 weeks followed by an increase to the predrug level after the fourth week. Over the whole observation period there was a correlation between neurophysiological data (alpha-1 power) and clinical symptomatology (BPRS total score; r = -0.7). Therefore, it can be concluded that quantitative EEG recordings are able to serve as a tool for the optimization of the depot neuroleptic treatment in schizophrenics.
authors.affiliation: Pro Science Private Research Institute GmbH, Linden, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Schellenberg
authors.forename: W
authors.initials: W
authors.lastname: Milch
authors.forename: A
authors.initials: A
authors.lastname: Schwarz
authors.forename: F
authors.initials: F
authors.lastname: Schober
authors.forename: W
authors.initials: W
authors.lastname: Dimpfel
mesh_terms: D000328:Adult; D000513:Alpha Rhythm; D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002540:Cerebral Cortex / Q000187:drug effects; D003692:Delayed-Action Preparations; D004569:Electroencephalography / Q000187:drug effects* / Q000295:instrumentation; D005260:Female; D005583:Fourier Analysis; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011569:Psychiatric Status Rating Scales; D012563:Schizophrenia, Paranoid / Q000188:drug therapy* / Q000523:psychology; D012815:Signal Processing, Computer-Assisted / Q000295:instrumentation; D009435:Synaptic Transmission / Q000187:drug effects
chemical_list: D014150:Antipsychotic Agents; D003692:Delayed-Action Preparations; C033563:haloperidol decanoate; D006220:Haloperidol